Page 96 - Human Use News Today

SHELTON, CT / ACCESSWIRE / January 4, 2023 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the Biotech

The Type II variation application for Enhertu® for adults with advanced non-small cell lung cancer has been validated by the EMA.

Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and...

Antibody drug conjugate Zynlonta can now be used in all European Union member states, Iceland, Norway and Liechtenstein.

Investegate announcements from Sanofi - Aventis Groupe, Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine

Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine - read this article along with other careers information, tips and advice on BioSpace

PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi said that the New England Journal of Medicine has published results from a positive Phase 3 trial showing adults and adolescents

The EC has granted conditional marketing authorisation for Sobi and ADC Therapeutics’ Zynlonta to treat diffuse large B-cell lymphoma.

Investegate announcements from AstraZeneca PLC, Lynparza approved in EU for prostate cancer

First PARP inhibitor and new hormonal agent combination approved for these patients in Europe AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced